banner
 
bar

program

slides

  test

syllabus
bar
 
 

The Evolving and Complex Therapeutic Landscape for Multiple Sclerosis

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period May 25, 2011 through May 25, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

3.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of patients with multiple sclerosis in the managed care environment.

Release Date:

May 25, 2011

Expiration Date:

May 25, 2013

Intended Audience:

This complimentary CME educational activity is designed for:

  • Neurologists
  • Multiple sclerosis specialists
  • Managed care medical directors
  • Managed care pharmacy directors

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by an Independent Educational Grant
from Teva Neuroscience.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Douglas R. Jeffery, MD, PhD – Program Chairman
Director, Multiple Sclerosis Center
Advance Neurology
Advance, NC

Consultant: Bayer, Biogen, TEVA, Serono, Pfizer, Acorda, Novartis
Speaker's Bureau: Bayer, Biogen, TEVA, Novartis, Acorda
Grant/Research Support: Bayer, Biogen, TEVA, Serono, Pfizer, Novartis



Howard Zwibel, MD
Founding Medical Director, Emeritus
Neuroscience Consultants
Comprehensive Multiple Sclerosis Center in affiliation with the National Multiple Sclerosis
Center Coral Gables, Florida
Baptist Health Doctors Hospital MS Center
Coral Gables, FL

Consultant TEVA, Acorda, Medscape
Speaker's Bureau: TEVA, Acorda,



Ronald DeBellis, PharmD
Professor and Chair, Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Colchester, VT

Consultant: Teva


Monica Mehta, PharmD
Assistant Professor
Arnold & Marie Schwartz College of Pharmacy and Health Sciences
Long Island University
Clinical Pharmacist, Infectious Diseases
Bronx-Lebanon Hospital Center
New York, NY

Nothing to disclose


Managed Care Panel Discussants
Gabriel Nova, MD
Medical Director
Preferred Medical Plan
Coral Gables, FL

Nothing to disclose


Ray Mummery, MD

Clinical Medical Officer
Dimension Health
Miami, FL

Nothing to disclose


John Knispel, MD, CPE, FACOG
Regional Medical Director
Florida Commercial Markets
Humana Inc.
Singer Island, FL

Nothing to disclose


Kirk Cianciolo, DO, MBA
Medical Administration, Urology
Southeastern Nova University
Gulfport, FL

Nothing to disclose

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this CME activity, the participants will be able to:

  • Develop a better understanding for how the likely approval of new MS therapies—including both oral and injectable agents—may change the risk-to-benefit analyses and influence long-term treatment decisions for MS treatment regimens implemented in the managed care setting
  • Understand, analyze, and project the clinical risks and benefits of emerging agents under evaluation for MS, and how managed care physicians and medical directors will need to evaluate such therapies for their managed care programs
  • Implement and understand the requirements for pharmacovigilance programs that are currently in place for MS therapies, and how pharmacoviligance programs for MS therapies used in managed care settings will need to adapt and change when potentially new, immunosuppressive therapies with a variable range of adverse effects and toxicities become available
  • Develop an understanding for how managed care physicians will assess current and established therapies in order to determine how therapy for MS should be initiated, monitored, and achieve the ideal balance between safety and efficacy for long-term therapy of MS

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
    · If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
Cladribine
CHAMPIONS

CHAMPS/ETOMS
Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Fingolimod
Glatiramer acetate
HIV
HTLV-1
Human IgG4
IFN b-1a
IFN b-1b
Immunosuppression

Laquinimod
INCOMIN
Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neurosyphilis
NMSS
Novantrone

optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Teriflunomide
Tysabri
white matter